Cargando…

The Cardiac Markers and Oxidative Stress Parameters in Advanced Non-Small Cell Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy

INTRODUCTION: Cardiotoxicity is a well known long-term consequence of lung cancer chemotherapy, however little is known about early subclinical changes in cardiac function. AIM: The goal of the study was to assess early cardiotoxic effects of cisplatin-containing chemotherapy in stage III and IV lun...

Descripción completa

Detalles Bibliográficos
Autores principales: Demkow, Urszula, Biatas-Chromiec, Beata, Stelmaszczyk-Emmel, Anna, Radzikowska, Elzbieta, Wiatr, Elzbieta, Radwan-Rohrenschef, Piotr, Szturmowicz, Monika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Communications and Publications Division (CPD) of the IFCC 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975326/
https://www.ncbi.nlm.nih.gov/pubmed/27683384
_version_ 1782446706204344320
author Demkow, Urszula
Biatas-Chromiec, Beata
Stelmaszczyk-Emmel, Anna
Radzikowska, Elzbieta
Wiatr, Elzbieta
Radwan-Rohrenschef, Piotr
Szturmowicz, Monika
author_facet Demkow, Urszula
Biatas-Chromiec, Beata
Stelmaszczyk-Emmel, Anna
Radzikowska, Elzbieta
Wiatr, Elzbieta
Radwan-Rohrenschef, Piotr
Szturmowicz, Monika
author_sort Demkow, Urszula
collection PubMed
description INTRODUCTION: Cardiotoxicity is a well known long-term consequence of lung cancer chemotherapy, however little is known about early subclinical changes in cardiac function. AIM: The goal of the study was to assess early cardiotoxic effects of cisplatin-containing chemotherapy in stage III and IV lung cancer patients, measuring serum levels of selected cardiac markers in relation to oxidant effects. METHODS: We quantified the immediate impact of chemotherapy on cardiac troponin T (TnT), creatine kinase-myocardial band (CK-MB) and N- terminal pro-brain natriuretic peptide (NT-proBNP) in blood samples obtained from 12 non-small cell lung cancer (NSCLC) patients. All markers were measured using commercially available immunoassays. To investigate the oxidant effects of cisplatin-containing chemotherapy, we evaluated reduced glutathione (GSH), nitrite (NO2), derivatives of reactive oxygen metabolites (d-ROMs) and thiols (SH). Samples were collected prior to chemotherapy and 1 day after the first cycle of cisplatin administration. RESULTS: Chemotherapy did not cause statistically significant elevations in serum CK-MB. Serum TnT levels were undetectable at both time points in 11 out of 12 patients with a threshold of 0.01 ng/ml. In the single patient with undetectable TnT at the baseline, after the first infusion TnT level reversibly rose to 0.03 ng/ml. The pre-treatment value of NT-proBNP was slightly elevated in 7 out of 12 lung cancer patients. In 1 case NT-proBNP level significantly increased after chemotherapy (from 221.8 to 1489.0 pg/ml p<0.001), in the remaining 11 patients it was stable Cisplatin-based combination chemotherapy induced significant nitrite production in 5 patients (p<0.05). The other measured oxidative stress parameters remained unchanged after the first infusion. CONCLUSION: This pilot study demonstrated occasional elevations of cardiac biomarkers during cisplatin administration. Administration of cisplatin-containing chemotherapy caused significant nitroxidative stress in some patients. The relevance of cardiovascular complications in cancer patients and identification individual risk factors of developing cardiovascular toxicity merit further evaluation.
format Online
Article
Text
id pubmed-4975326
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher The Communications and Publications Division (CPD) of the IFCC
record_format MEDLINE/PubMed
spelling pubmed-49753262016-09-28 The Cardiac Markers and Oxidative Stress Parameters in Advanced Non-Small Cell Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy Demkow, Urszula Biatas-Chromiec, Beata Stelmaszczyk-Emmel, Anna Radzikowska, Elzbieta Wiatr, Elzbieta Radwan-Rohrenschef, Piotr Szturmowicz, Monika EJIFCC Research Article INTRODUCTION: Cardiotoxicity is a well known long-term consequence of lung cancer chemotherapy, however little is known about early subclinical changes in cardiac function. AIM: The goal of the study was to assess early cardiotoxic effects of cisplatin-containing chemotherapy in stage III and IV lung cancer patients, measuring serum levels of selected cardiac markers in relation to oxidant effects. METHODS: We quantified the immediate impact of chemotherapy on cardiac troponin T (TnT), creatine kinase-myocardial band (CK-MB) and N- terminal pro-brain natriuretic peptide (NT-proBNP) in blood samples obtained from 12 non-small cell lung cancer (NSCLC) patients. All markers were measured using commercially available immunoassays. To investigate the oxidant effects of cisplatin-containing chemotherapy, we evaluated reduced glutathione (GSH), nitrite (NO2), derivatives of reactive oxygen metabolites (d-ROMs) and thiols (SH). Samples were collected prior to chemotherapy and 1 day after the first cycle of cisplatin administration. RESULTS: Chemotherapy did not cause statistically significant elevations in serum CK-MB. Serum TnT levels were undetectable at both time points in 11 out of 12 patients with a threshold of 0.01 ng/ml. In the single patient with undetectable TnT at the baseline, after the first infusion TnT level reversibly rose to 0.03 ng/ml. The pre-treatment value of NT-proBNP was slightly elevated in 7 out of 12 lung cancer patients. In 1 case NT-proBNP level significantly increased after chemotherapy (from 221.8 to 1489.0 pg/ml p<0.001), in the remaining 11 patients it was stable Cisplatin-based combination chemotherapy induced significant nitrite production in 5 patients (p<0.05). The other measured oxidative stress parameters remained unchanged after the first infusion. CONCLUSION: This pilot study demonstrated occasional elevations of cardiac biomarkers during cisplatin administration. Administration of cisplatin-containing chemotherapy caused significant nitroxidative stress in some patients. The relevance of cardiovascular complications in cancer patients and identification individual risk factors of developing cardiovascular toxicity merit further evaluation. The Communications and Publications Division (CPD) of the IFCC 2011-03-14 /pmc/articles/PMC4975326/ /pubmed/27683384 Text en Copyright © 2011 International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). All rights reserved. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Demkow, Urszula
Biatas-Chromiec, Beata
Stelmaszczyk-Emmel, Anna
Radzikowska, Elzbieta
Wiatr, Elzbieta
Radwan-Rohrenschef, Piotr
Szturmowicz, Monika
The Cardiac Markers and Oxidative Stress Parameters in Advanced Non-Small Cell Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy
title The Cardiac Markers and Oxidative Stress Parameters in Advanced Non-Small Cell Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy
title_full The Cardiac Markers and Oxidative Stress Parameters in Advanced Non-Small Cell Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy
title_fullStr The Cardiac Markers and Oxidative Stress Parameters in Advanced Non-Small Cell Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy
title_full_unstemmed The Cardiac Markers and Oxidative Stress Parameters in Advanced Non-Small Cell Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy
title_short The Cardiac Markers and Oxidative Stress Parameters in Advanced Non-Small Cell Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy
title_sort cardiac markers and oxidative stress parameters in advanced non-small cell lung cancer patients receiving cisplatin-based chemotherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975326/
https://www.ncbi.nlm.nih.gov/pubmed/27683384
work_keys_str_mv AT demkowurszula thecardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy
AT biataschromiecbeata thecardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy
AT stelmaszczykemmelanna thecardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy
AT radzikowskaelzbieta thecardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy
AT wiatrelzbieta thecardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy
AT radwanrohrenschefpiotr thecardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy
AT szturmowiczmonika thecardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy
AT demkowurszula cardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy
AT biataschromiecbeata cardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy
AT stelmaszczykemmelanna cardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy
AT radzikowskaelzbieta cardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy
AT wiatrelzbieta cardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy
AT radwanrohrenschefpiotr cardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy
AT szturmowiczmonika cardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy